Harrow Health, Inc.

NASDAQ:HROW

Drug Manufacturers - Specialty & Generic

Healthcare
$32.16 +0.29%

+$0.12 today

Market cap
$1.21B
Beta
0.28
P/E (TTM)
-104.7
EPS (TTM)
-$0.40
52W Low $28.54High $54.85

Volume 0.87M

Average 0.75M

HROW Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Harrow Health, Inc.NASDAQ: HROW

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital grows, but more slowly than its trailing trend

Q1 FY2026 other working capital of $1.49M (cash outflow) rose 0.2% year over year, behind the +174.7% change in trailing-twelve-month other working capital. Sequentially, it rose 789.3% from the prior quarter.

Context

  • Other working capital amounted to 1.0% of revenue in FY2025, unchanged from a year earlier.
  • Other working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.2% toward the trailing-twelve-month pace of +174.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.49M+789.3% QoQ
Last fiscal yearDec 2025
$2.6M+226.6% YoY
LTMMar 2026
$2.6M+174.7% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.2%——
1 year+226.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
2.6M USD
Year-over-year change
+226.6%
4-year CAGR
+124.2%

Other Working Capital vs competitors

How HROW compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +174.7% is the 2nd highest of 8, against a peer median of -62.7%.
  • Other working capital amounts to 1.0% of revenue for HROW, versus a peer median of 60.6%.
HROW Competitors
Other Working Capital for HROW and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$57.42M USD+573.2%—8.4%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$8.59M USD-62.7%+228.3%112.8%
BLCOBausch + Lomb CorporationLTM Jun 2026$7.26M USD-39.5%—0.1%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$2.74M USD-14.3%—822.7%
HROWHarrow Health, Inc.LTM Mar 2026$2.6M USD+174.7%—1.0%
KODKodiak Sciences Inc.LTM Sep 2026$1.59M USD-267.1%——
OCSOculis Holding AGLTM Mar 2026CHF 1.53M CHF-81.9%—303.8%
TTRXTurn Therapeutics Inc.LTM Mar 2026$268.43K USD———
OCULOcular Therapeutix, Inc.LTM Mar 2026$90K USD-100.9%+36.8%0.2%
Peer median (excluding HROW) —-62.7%+132.6%60.6%

Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(18.01M)(14.09M)(24.41M)(17.48M)(5.14M)
Depreciation & Amortization2.4M3.67M12.34M14.54M19.68M
Deferred Income Tax00000
Stock-Based Compensation5.75M7.97M15.7M17.62M12.5M
Change in Working Capital(253K)(5.57M)(7.14M)(44.63M)185K
Accounts Receivables(1.83M)(1.86M)(30.34M)(80.23M)5.01M
Inventory(255K)(2.32M)(4.33M)165K(2.82M)
Accounts Payables1.73M933K31.8M37.5M(4.61M)
Other Working Capital103K(2.32M)(4.26M)(2.06M)2.6M
Other Non-Cash Items15.2M9.72M7.35M7.75M16.64M
Operating Cash Flow5.08M1.71M3.84M(22.2M)43.86M
Capital Expenditures(28.51M)(7.77M)(152.55M)(38.67M)(1.1M)
Acquisitions (Net)9.83M000(4.36M)
Purchases of Investments00000
Sales of Investments9.83M005.51M0
Other Investing Activities(36.55M)854K(151.09M)(37.08M)(215K)
Investing Cash Flow(18.69M)(1.74M)(152.55M)(33.16M)(5.46M)
Debt Repayment71.07M31.72M74.64M29.78M11.84M
Common Stock Issued022.66M64.52M0467K
Common Stock Repurchased00000
Dividends Paid(127K)0000
Other Financing Activities(19.12M)(234K)(12.63M)(1.25M)(25.04M)
Financing Cash Flow51.47M54.14M126.53M28.53M(12.72M)
Effect of Forex Changes00000
Net Change in Cash37.87M54.1M(22.19M)(26.84M)25.68M
Free Cash Flow(23.43M)(6.07M)(148.71M)(60.88M)42.76M

Harrow Health, Inc.

NASDAQ:HROW

Intrinsic Alpha fair value

Locked

Current Price

$32.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.